Search





Search





Incyte's skin disease drug meets main goal in two late-stage studies

ReutersMar 17, 2025 11:06 AM

March 17 (Reuters) - Incyte INCY.O said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Tradingkey

Recommended Articles

IonQ vs. Rigetti Computing: Which Quantum Computing Stock Has the Edge Now?

TradingKey - One of the most uncertain areas in the marketplace today, quantum computing, is possibly the most speculative.

What company Is ASML? Between ASML and AMD, Which Is a Better Investment?

TradingKey - ASML Holding N.V. (NASDAQ: ASML) is not a chip designer; instead, it's best understood as a supplier of equipment for producing semiconductors (sometimes referred to as chips).

Amazon Stock: 4 Pillars Supporting a Buy Thesis in a Cautious Market

TradingKey - In 2025, AMZN has underperformed vs. the rest of the S&P 500 due to concerns about high infrastructure spending and uncertainty around the timing of cash flow from AI investments.

SpaceX IPO Guide: Can You Buy SpaceX IPO Shares on Robinhood? How Can Investors in Asia and Europe Buy SpaceX IPO Shares?

Looking to invest in the $1.75T SpaceX IPO? Discover if Robinhood and E*Trade offer access, and explore step-by-step guides for retail investors in Singapore, Hong Kong, the UK, and the EU to secure their shares.

What Needs to Happen for Tesla to Succeed in the Next Few Years?

TradingKey - The stock of Tesla (TSLA) is currently in contention as the bearish side has the advantage.

Tradingkey

KeyAI

